Mazor Robotics Ltd. (NASDAQ:MZOR)’s share price traded down 0.6% during mid-day trading on Friday . The company traded as low as $52.67 and last traded at $54.42. 416,543 shares traded hands during mid-day trading, an increase of 5% from the average session volume of 397,226 shares. The stock had previously closed at $54.74.

Several brokerages have commented on MZOR. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics in a research note on Thursday, July 6th. Barclays PLC cut shares of Mazor Robotics from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $55.00 to $34.00 in a report on Thursday. Zacks Investment Research cut shares of Mazor Robotics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services set a $54.00 target price on shares of Mazor Robotics and gave the stock a “buy” rating in a report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. Mazor Robotics has a consensus rating of “Hold” and an average target price of $37.67.

The stock’s 50 day moving average price is $49.50 and its 200 day moving average price is $40.32. The company’s market capitalization is $1.30 billion.

Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $15.46 million during the quarter, compared to analyst estimates of $15.38 million. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The business’s quarterly revenue was up 86.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. On average, equities research analysts expect that Mazor Robotics Ltd. will post ($0.77) earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Lord Abbett & CO. LLC bought a new position in Mazor Robotics in the second quarter worth $2,421,000. Raymond James Financial Services Advisors Inc. bought a new position in Mazor Robotics in the second quarter worth $770,000. Royal Bank of Canada raised its holdings in Mazor Robotics by 9.2% in the second quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock worth $749,000 after purchasing an additional 1,819 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after purchasing an additional 641 shares in the last quarter. Finally, Messner & Smith Theme Value Investment Management Ltd. CA raised its holdings in Mazor Robotics by 23.6% in the second quarter. Messner & Smith Theme Value Investment Management Ltd. CA now owns 36,201 shares of the medical instruments supplier’s stock worth $1,252,000 after purchasing an additional 6,919 shares in the last quarter. 25.92% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/22/mazor-robotics-ltd-mzor-shares-down-0-6.html.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.